Annovis Bio Files Patents for Innovative Therapies in Neurodegenerative Disease Treatment

Annovis Bio

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has made strides in the fight against neurodegenerative diseases with the filing of three new patents. These cover novel combination therapies involving their lead compound, buntanetap, alongside Trulicity (dulaglutide) and Viagra (sildenafil). This strategic move marks a significant advancement in developing treatments that could potentially enhance cognitive function in patients with Alzheimer’s Disease (AD) and Parkinson’s Disease (PD).

Buntanetap, known for its ability to inhibit neurotoxic protein production, has demonstrated promising results in clinical trials. It has shown potential to improve cognition in early Alzheimer’s patients and halt cognitive decline in Parkinson’s patients. Recent preclinical studies revealed that combining buntanetap with Trulicity, a GLP-1 agonist, or Viagra, a PDE5 inhibitor, led to cognitive improvements in Alzheimer’s mouse models, surpassing levels seen in healthy controls.

The patents filed include combinations of buntanetap with Trulicity, Viagra, and a combination of all three. This approach aims to leverage the synergistic effects of these drugs, offering a multifaceted strategy to enhance cognitive function and combat dementia.

Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, expressed optimism about these developments: “Our early data suggests a strong synergistic effect from combining these drugs, resulting in significant cognitive enhancement. The combination of buntanetap with Trulicity and Viagra not only has the potential to restore cognition to healthy levels but also to improve it beyond normal, offering new hope in the fight against dementia.”

With buntanetap having completed Phase 3 studies as a standalone treatment and the other drugs being FDA-approved, these combinations are well-positioned for Phase 3 human trials. This promising development could pave the way for more effective treatments for those suffering from neurodegenerative conditions, bringing new hope to patients and their families.

READ:  Traws Pharma Reports Positive Phase 1 Results for Influenza Therapy Tivoxavir Marboxil

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.